發(fā)布時間：2018-02-16 06:57

  本文關(guān)鍵詞： 無形資產(chǎn) 質(zhì)量評價 國藥股份 醫(yī)藥行業(yè)　出處：《蘭州財經(jīng)大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

【摘要】：無形資產(chǎn)質(zhì)量評價,是指以提升企業(yè)價值為目標(biāo),對無形資產(chǎn)滿足企業(yè)異質(zhì)性、盈利性和持續(xù)發(fā)展需求程度的評價。無形資產(chǎn)質(zhì)量評價能使企業(yè)準(zhǔn)確了解無形資產(chǎn)的現(xiàn)狀,并通過具體分析發(fā)現(xiàn)導(dǎo)致無形資產(chǎn)質(zhì)量問題的因素,從而針對具體問題提出改進(jìn)建議。本文界定了無形資產(chǎn)和無形資產(chǎn)質(zhì)量評價的概念,對相關(guān)理論進(jìn)行了分析,結(jié)合醫(yī)藥行業(yè)無形資產(chǎn)的特殊性,總結(jié)出醫(yī)藥行業(yè)無形資產(chǎn)質(zhì)量評價的內(nèi)容,同時參考前人對無形資產(chǎn)質(zhì)量的研究成果,構(gòu)建出無形資產(chǎn)質(zhì)量評價指標(biāo)體系。對100家上市醫(yī)藥企業(yè)各無形資產(chǎn)質(zhì)量評價指標(biāo)進(jìn)行聚類分析,得出醫(yī)藥行業(yè)無形資產(chǎn)質(zhì)量評價標(biāo)準(zhǔn),并對醫(yī)藥行業(yè)無形資產(chǎn)質(zhì)量評價方法進(jìn)行說明。醫(yī)藥行業(yè)無形資產(chǎn)質(zhì)量評價指標(biāo)體系、評價標(biāo)準(zhǔn)和評價方法構(gòu)成醫(yī)藥行業(yè)無形資產(chǎn)質(zhì)量評價模式。運用該評價模式以云南白藥為參照,從創(chuàng)新能力、盈利能力和發(fā)展能力三方面對國藥股份無形資產(chǎn)整體質(zhì)量進(jìn)行評價,以及從知識類無形資產(chǎn)、人力資源資產(chǎn)和市場類無形資產(chǎn)三方面對各類無形資產(chǎn)質(zhì)量進(jìn)行評價,得出評價結(jié)論:國藥股份無形資產(chǎn)技術(shù)創(chuàng)新能力較差,市場競爭能力中等,持續(xù)發(fā)展能力較差;知識類無形資產(chǎn)質(zhì)量差,人力資源質(zhì)量中等,市場類無形資產(chǎn)質(zhì)量較差。并針對無形資產(chǎn)質(zhì)量存在的問題提出改進(jìn)建議。本文可能的貢獻(xiàn)之處主要有:1.專門研究無形資產(chǎn)質(zhì)量評價問題2.構(gòu)建出醫(yī)藥行業(yè)無形資產(chǎn)質(zhì)量評價模式3.運用構(gòu)建的評價模式對國藥股份無形資產(chǎn)質(zhì)量進(jìn)行了具體評價,為今后無形資產(chǎn)質(zhì)量評價模式及其應(yīng)用研究略盡綿薄之力。
[Abstract]:The quality evaluation of intangible assets refers to the evaluation of the degree to which the intangible assets meet the requirements of heterogeneity, profitability and sustainable development with the aim of enhancing the value of the enterprises. The evaluation of the quality of intangible assets enables the enterprises to accurately understand the present situation of the intangible assets. Through concrete analysis, the author finds out the factors that lead to the quality problems of intangible assets, and then puts forward some suggestions for improvement. This paper defines the concept of intangible assets and intangible assets quality evaluation, and analyzes the relevant theories. Combined with the particularity of the intangible assets in the pharmaceutical industry, this paper summarizes the contents of the quality evaluation of the intangible assets in the pharmaceutical industry, and at the same time refers to the previous research results on the quality of the intangible assets. The evaluation index system of intangible assets quality is constructed. The evaluation index of intangible assets quality in 100 listed pharmaceutical enterprises is analyzed by cluster analysis, and the evaluation standard of intangible assets quality in pharmaceutical industry is obtained. The evaluation index system of intangible assets quality in pharmaceutical industry is introduced. The evaluation criteria and methods constitute the evaluation model of intangible assets quality in the pharmaceutical industry. It evaluates the overall quality of intangible assets of Chinese medicine shares from three aspects: profitability and development ability, and evaluates the quality of intangible assets from three aspects: knowledge intangible assets, human resources assets and market intangible assets. The conclusions are as follows: the technical innovation ability of intangible assets of Chinese medicine stock is poor, the market competition ability is medium, the ability of sustained development is poor, the quality of intangible assets of knowledge class is poor, the quality of human resources is medium. The quality of intangible assets in the market is poor, and some suggestions are put forward to improve the quality of intangible assets. The possible contribution of this paper is mainly in the following aspects: 1. Special research on the quality evaluation of intangible assets 2.Constructing the intangible assets in the pharmaceutical industry. The evaluation mode of assets quality. 3. The evaluation model is used to evaluate the quality of intangible assets of shares of Chinese medicine. For the future intangible assets quality evaluation model and its application research do a little bit.
【學(xué)位授予單位】：蘭州財經(jīng)大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：F426.72;F406.7

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 徐軍;;國藥股份 長期發(fā)展前景穩(wěn)定[J];證券導(dǎo)刊;2008年29期

2 邱乾謀;;國藥股份淘金醫(yī)藥物流[J];中國物流與采購;2006年03期

3 ;申銀萬國 國藥股份:行業(yè)壓力不改增長趨勢[J];證券導(dǎo)刊;2008年19期

4 ;[J];;年期

相關(guān)重要報紙文章 前10條

1 蔡曉銘;國藥股份　　投資收益大幅增長 　　凈利潤增長44%[N];證券時報;2006年

2 習(xí)文;國藥股份延伸“專營”鏈條[N];中國醫(yī)藥報;2004年

3 習(xí)文;并購：國藥股份的“引擎”[N];醫(yī)藥經(jīng)濟(jì)報;2005年

4 本報實習(xí)記者　 高建鋒;“復(fù)星系”間接入股國藥股份[N];中國證券報;2006年

5 本報記者　 陳鋼;國藥股份盈利能力居行業(yè)領(lǐng)先[N];上海證券報;2006年

6 本報記者　 陳鋼;國藥股份修改方案提高對價[N];上海證券報;2006年

7 雪墨;國藥股份：業(yè)績持續(xù)增長競爭優(yōu)勢彰顯[N];中國醫(yī)藥報;2007年

8 龍躍;國藥股份(600511)渠道成熟 成長確定[N];中國證券報;2007年

9 中銀國際;國藥股份：未來幾年將保持較高增速[N];上海證券報;2007年

10 銀河證券 李鷹鵬邋實習(xí)記者 張勤峰;國藥股份 業(yè)績穩(wěn)定增長[N];中國證券報;2008年

相關(guān)碩士學(xué)位論文 前1條

1 劉鑫;國藥股份無形資產(chǎn)質(zhì)量評價研究[D];蘭州財經(jīng)大學(xué);2016年

，

本文編號：1514925